Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q8WUD6
UPID:
CHPT1_HUMAN
Alternative names:
AAPT1-like protein; Diacylglycerol cholinephosphotransferase 1
Alternative UPACC:
Q8WUD6; B3KQM2; Q7Z7H0; Q7Z7H1; Q7Z7H2; Q8IWQ4; Q8IWQ5; Q8WYI4; Q9NRQ6; Q9NRQ7; Q9Y6M6
Background:
Cholinephosphotransferase 1, also known as Diacylglycerol cholinephosphotransferase 1 and AAPT1-like protein, is pivotal in phosphatidylcholine (PC) synthesis. It catalyzes the transfer of choline phosphate to diacylglycerol (DAG), producing PC, essential for vesicular membrane formation and maintenance.
Therapeutic significance:
Understanding the role of Cholinephosphotransferase 1 could open doors to potential therapeutic strategies.